RBC Capital maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) and lowered its price target to $118.00 (from $125.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE